Susan Kemp, MD
Internal Medicine · Shreveport, LANPI 1972586527
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,342 and has fallen 78.6% since, to $288 in 2025.
Across 160 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$672
- Organogenesis Inc.$405
- AstraZeneca$381
- AbbVie$194
- Smith+Nephew$181
- Melinta Therapeutics, LLC$158
- plus $1K from 22 others
Across 3 payments — averaging $3099.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6K
- Novo Nordisk AS$4K
What the payments were for
- Food & beverage$3,126100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $672 |
| Organogenesis Inc. | 11 | $405 |
| AstraZeneca(2 entities) | 21 | $381 |
| AbbVie | 12 | $194 |
| Smith+Nephew | 8 | $181 |
| Melinta Therapeutics, LLC | 9 | $158 |
| Johnson & Johnson | 11 | $134 |
| UCB, Inc. | 1 | $115 |
| Paratek Pharmaceuticals, Inc. | 5 | $110 |
| Merck | 7 | $101 |
| GSK | 5 | $82 |
| Mimedx Group, Inc. | 3 | $68 |
| Pfizer | 4 | $64 |
| Lilly USA, LLC | 4 | $61 |
| Inari Medical, Inc. | 2 | $56 |
| Boehringer Ingelheim | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 4 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Astellas Pharma US Inc | 3 | $35 |
| KCI USA, Inc. | 2 | $30 |
| Integra Lifesciences Corporation | 1 | $28 |
| Urgo Medical North America, LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Solventum Corporation | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,130 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 85 | $104,074 |
| OzempicSemaglutide | 73 | $94,233 |
| JanuviaSitagliptin Phosphate | 63 | $64,845 |
| EliquisApixaban | 47 | $57,124 |
| JardianceEmpagliflozin | 42 | $37,382 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $20,534 |
| TrulicityDulaglutide | 16 | $20,055 |
| FarxigaDapagliflozin Propanediol | 12 | $12,084 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $11,143 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,560 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $6,301 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $5,656 |
| Atorvastatin Calcium | 255 | $2,646 |
| Celecoxib | 23 | $2,613 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $61 | $124,129101 claims |
| Novo NordiskOzempic | $672 | $94,23373 claims |
| MerckJanuvia, Janumet Xr | $101 | $75,98878 claims |
| PfizerEliquis | $64 | $57,12447 claims |
| Boehringer IngelheimJardiance | $46 | $37,38242 claims |
| AstraZenecaFarxiga, Symbicort | $381 | $19,64440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Shreveport
- Rajan KhannaShreveport$54K
- Wendell WallShreveport$25K
- Bharat SachdevaShreveport$24K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- Paul RushingShreveport$13K
- Allan Matriano-LimShreveport$12K
- Scott McRightShreveport$12K
- Furqan AkhtarShreveport$11K
- Roan FlennikenShreveport$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.